McKesson HBOC installs integrated PACS
McKesson HBOC installs integrated PACSMcKesson HBOC has reached a key milestone in its bid for an increased profile in the PACS market. Baptist Memorial Healthcare Corp. (BMHCC) in Memphis, TN, has integrated the firm’s MedVision PACS with
McKesson HBOC installs integrated PACS
McKesson HBOC has reached a key milestone in its bid for an increased profile in the PACS market. Baptist Memorial Healthcare Corp. (BMHCC) in Memphis, TN, has integrated the firms MedVision PACS with electronic patient record software at its newest facility, Baptist Memorial Hospital-Collierville. The Baptist site is the first to implement the Alpharetta, GA-based companys infoPACS concept, where PACS is integrated as part of an enterprise-wide information system.
BMHCC plans to implement similar systems at all 16 of its hospitals in Tennessee, Arkansas, and Mississippi, according to McKesson HBOC. The hospital chain is already using the electronic patient folder module of the firms Pathways Image Manager offering at two larger hospitals in Memphis.
First articulated by medical imaging and document management firm Imnet Systems at the 1996 RSNA meeting, the infoPACS concept has taken several twists and turns before achieving commercialization. In August 1998, fellow HIS firm HBOC & Company acquired Imnet (PNN 9/98). Medical supply giant McKesson subsequently purchased HBOC in January 1999 (PNN 2/99).
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
